• Autonomix Medical disclosed that two abstracts on its transvascular nerve-targeting device platform were accepted for presentation at EuroPCR 2026 in Paris on May 19-22, 2026.
• The presentations will cover long-term findings on pain mitigation in pancreatic cancer using the company’s denervation approach, alongside a separate overview of its precision-guided technology.
• The acceptance signals rising clinical interest in the platform, which Autonomix is positioning for broader use in conditions where nerve signaling drives symptoms.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Autonomix Medical Inc. published the original content used to generate this news brief on May 18, 2026, and is solely responsible for the information contained therein.